Antihypertensive N-piperazinylalkanoylanilides
    3.
    发明授权
    Antihypertensive N-piperazinylalkanoylanilides 失效
    抗高血压的N-哌嗪基烷酰基酰苯胺

    公开(公告)号:US4940711A

    公开(公告)日:1990-07-10

    申请号:US373451

    申请日:1989-06-30

    CPC分类号: C07D295/15 C07D317/66

    摘要: N-piperazinylalkanoylanilides of the formula ##STR1## wherein n is 0, 1 or 2, each of R and R.sub.1 is H or alkyl, and each of R.sub.2, R.sub.3 and R.sub.4 is H, halogen, alkyl, hydroxyalkyl, alkoxy, aralkoxy, alkylthio, aralkylthio, alkylsulphonyl, alkylsulphenyl, NO.sub.2, NH.sub.2, alkylamino, acylamino, ureido, alkylureido, alkylsulphonylamino, CF.sub.3, acyl, CN, COOH, alkoxycarbonyl, NH.sub.2 CO, SO.sub.3 H, guanidinosulphonyl, carbamoyloxy, OH, acyloxy, alkylsulphonyloxy, alkylenedioxy or SO.sub.2 NR.sub.5 R.sub.6 wherein each of R.sub.5 and R.sub.6 is H, alkyl, aryl or acyl and their pharmaceutically acceptable acid addition salts, are antihypertensive agents.

    摘要翻译: 式(I)的N-哌嗪基烷酰基酰苯胺其中n为0,1或2,R和R 1各自为H或烷基,R 2,R 3和R 4各自为H,卤素,烷基,羟基烷基,烷氧基, 芳烷氧基,烷硫基,芳烷硫基,烷基磺酰基,烷基亚磺酰基,NO2,NH2,烷基氨基,酰基氨基,脲基,烷基脲基,酰基氨基,脲基,烷基脲基,烷基磺酰基氨基,CF3,酰基,CN,COOH,烷氧基羰基,NH2CO,SO3H,胍基磺酰基,氨基甲酰氧基,OH,酰氧基,烷基磺酰氧基,亚烷基二氧基或 SO 2 NR 5 R 6,其中R 5和R 6各自为H,烷基,芳基或酰基及其药学上可接受的酸加成盐,为抗高血压药。

    Lercanidipine salts
    4.
    发明授权
    Lercanidipine salts 失效
    Lercanidipine盐

    公开(公告)号:US07683179B2

    公开(公告)日:2010-03-23

    申请号:US11211769

    申请日:2005-08-24

    IPC分类号: C07D213/80

    CPC分类号: C07D211/90

    摘要: The present invention relates to new addition salts of lercanidipine comprising lercanidipine and an acid counterion wherein the acid counterion is selected from the group consisting of: (i) inorganic acids, (ii) sulfonic acids, (iii) monocarboxylic acids, (iv) dicarboxylic acids, (v) tricarboxylic acids, and (vi) aromatic sulfonimides, with the proviso that said acid counterion is not hydrochloric acid.

    摘要翻译: 本发明涉及氯卡地平的新加成盐,其包括氯卡地平和酸抗衡离子,其中酸抗衡离子选自:(i)无机酸,(ii)磺酸,(iii)一元羧酸,(ⅳ)二羧酸 酸,(v)三羧酸和(vi)芳族亚磺酰亚胺,条件是所述酸抗衡离子不是盐酸。

    ACID ADDITION SALTS OF THIENOPYRANCARBOXAMIDE DERIVATIVES
    5.
    发明申请
    ACID ADDITION SALTS OF THIENOPYRANCARBOXAMIDE DERIVATIVES 审中-公开
    三苯甲酰胺衍生物的酸添加量

    公开(公告)号:US20070185129A1

    公开(公告)日:2007-08-09

    申请号:US11671350

    申请日:2007-02-05

    IPC分类号: A61K31/496 C07D495/02

    CPC分类号: C07D495/04

    摘要: The invention relates to novel addition salts of N-{3-[4-(2-Methoxyphenyl)-1-piperazinyl]propyl}-7-oxo-5-trifluoromethyl-7H-thieno[3,2-b]pyran-3-carboxamide, comprising N-{3-[4-(2-Methoxyphenyl)-1-piperazinyl]propyl}-7-oxo-5-trifluoromethyl-7H-thieno[3,2-b]pyran-3-carboxamide and an acid counterion wherein the acid counterion is selected from the group consisting of: (i) inorganic acids and (ii) sulfonic acids.

    摘要翻译: 本发明涉及N- {3- [4-(2-甲氧基苯基)-1-哌嗪基]丙基} -7-氧代-5-三氟甲基-7H-噻吩并[3,2-b]吡喃-3 - 甲酰胺,其包含N- {3- [4-(2-甲氧基苯基)-1-哌嗪基]丙基} -7-氧代-5-三氟甲基-7H-噻吩并[3,2-b]吡喃-3-甲酰胺和 酸抗衡离子,其中酸抗衡离子选自:(i)无机酸和(ii)磺酸。

    Spiroheterocyclic compounds as mGlu5 antagonists
    10.
    发明授权
    Spiroheterocyclic compounds as mGlu5 antagonists 有权
    螺杂环化合物作为mGlu5拮抗剂

    公开(公告)号:US08580962B2

    公开(公告)日:2013-11-12

    申请号:US13180166

    申请日:2011-07-11

    IPC分类号: A61K31/44 C07D213/00

    CPC分类号: C07D498/10 C07D491/10

    摘要: The invention is directed to methods of using antagonists selective for the metabotropic mGlu5 receptor to treat conditions of neuromuscular dysfunction of the lower urinary tract in a mammal. Provided are methods of treating a mammal suffering from a condition of neuromuscular dysfunction of the lower urinary tract by administering a selective mGlu5 antagonist. The selective mGlu5 antagonist may be administered alone or in combination with one or more additional therapeutic agents for treating such a condition. Also provided are methods of identifying selective mGlu5 antagonists that are useful for treating neuromuscular dysfunction of the lower urinary tract in a mammal. Methods for treating migraine and gastroesophageal reflux disease (GERD) using selective mGlu5 antagonists are also disclosed.

    摘要翻译: 本发明涉及使用选择性代谢型mGlu5受体的拮抗剂治疗哺乳动物下泌尿道神经肌肉功能障碍的方法。 提供了通过施用选择性mGlu5拮抗剂治疗患有下尿路神经肌肉功能障碍的哺乳动物的方法。 选择性mGlu5拮抗剂可以单独施用或与一种或多种用于治疗这种病症的其它治疗剂组合施用。 还提供鉴定可用于治疗哺乳动物下泌尿道神经肌肉功能障碍的选择性mGlu5拮抗剂的方法。 还公开了使用选择性mGlu5拮抗剂治疗偏头痛和胃食管反流病(GERD)的方法。